NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics ARQT Tighter Trailing Losses Test Bullish Profitability Narrative
Arcutis Biotherapeutics (ARQT) opened Q1 2026 with total revenue of US$105.4 million, basic EPS of a US$0.09 loss, and a net income loss of US$11.3 million, while its trailing twelve month revenue stood at US$415.6 million and basic EPS at a US$0.02 loss. Over recent quarters, the company reported revenue moving from US$71.4 million in Q4 2024 to US$129.5 million in Q4 2025, with quarterly basic EPS shifting between a loss of US$0.20 in Q1 2025 and a profit of US$0.14 in Q4 2025. For...